Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer (Q40126331)
Jump to navigation
Jump to search
scientific article published on 5 February 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer |
scientific article published on 5 February 2008 |
Statements
1 reference
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer (English)
1 reference
F Anthony Greco
1 reference
Philip Bonomi
1 reference
Jeffrey Crawford
1 reference
Yun Oh
1 reference
Wendy Halpern
1 reference
Larry Lo
1 reference
Gilles Gallant
1 reference
Jerry Klein
1 reference
5 February 2008
1 reference
1 reference
Identifiers
1 reference